Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

171 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T. Fridrik MA, et al. Among authors: radaszkiewicz t. Ann Hematol. 1997 Oct;75(4):135-40. doi: 10.1007/s002770050330. Ann Hematol. 1997. PMID: 9402845 Clinical Trial.
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T. Fridrik MA, et al. Among authors: radaszkiewicz t. J Clin Oncol. 1996 Jan;14(1):227-32. doi: 10.1200/JCO.1996.14.1.227. J Clin Oncol. 1996. PMID: 8558202 Clinical Trial.
171 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page